PMID- 22143984
OWN - NLM
STAT- MEDLINE
DCOM- 20120831
LR  - 20171116
IS  - 1552-4957 (Electronic)
IS  - 1552-4949 (Linking)
VI  - 82
IP  - 3
DP  - 2012 May
TI  - Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients 
      with chronic lymphocytic leukemia.
PG  - 145-50
LID - 10.1002/cyto.b.21002 [doi]
AB  - BACKGROUND: In patients with chronic lymphocytic leukemia (CLL), aberrant 
      expression of the T-lineage antigen CD8 was reported in low frequencies. The 
      clinical impact of this phenomenon remains in discussion. METHODS: We analyzed 
      5,523 patients with CLL (21-97 years) by multiparametric flow cytometry and 
      performed fluorescence in situ hybridization (FISH), immunoglobulin heavy chain 
      variable (IGHV) region mutational status analysis, and clinical outcome studies. 
      RESULTS: CD8 was positive in 61/5,523 (1.1%) patients. ZAP-70 expression amounted 
      to a mean of 25.4% in CD8-positive vs. 28.2% in CD8-negative cases (n.s.), CD38 
      expression to a mean of 38.6% vs. 34.0% (n.s.). Cytogenetic alterations did not 
      differ significantly [CD8-positive vs. CD8-negative: 13q deletion: 24/36 (66.7%) 
      vs. 2,015/3,368 (59.8%); trisomy 12:7/35 (20.0%) vs. 487/3,357 (14.5%); 11q 
      deletion: 6/35 (17.1%) vs. 360/3,354 (10.7%)]. A mutated IGHV status showed 
      similar frequency in CD8-positive and CD8-negative cases (31/44; 70.5% vs. 
      1,700/2,816; 60.4%; n.s.). CD8-positive patients had a shorter median time to 
      treatment compared with CD8-negative patients (12.0 vs. 77.1 months, P = 0.008). 
      In univariable Cox analysis, CD8-positivity adversely influenced median TTT (P = 
      0.011). In multivariable analysis, the strongest parameters were hemoglobin level 
      and mutated IGHV status (P < 0.001 for both) but CD8-positivity was still 
      relevant (P = 0.074). CONCLUSIONS: This study confirms that CD8 expression is a 
      recurrent albeit rare phenomenon in patients with CLL and suggests that CD8 
      expression has an adverse prognostic impact. Therefore, CD8 expression should be 
      further investigated for its potential to contribute to risk stratification in 
      patients with CLL.
CI  - Copyright (c) 2011 International Clinical Cytometry Society.
FAU - Kern, Wolfgang
AU  - Kern W
AD  - MLL Munich Leukemia Laboratory, Munich, Germany. wolfgang.kern@mll.com
FAU - Bacher, Ulrike
AU  - Bacher U
FAU - Haferlach, Claudia
AU  - Haferlach C
FAU - Alpermann, Tamara
AU  - Alpermann T
FAU - Dicker, Frank
AU  - Dicker F
FAU - Schnittger, Susanne
AU  - Schnittger S
FAU - Haferlach, Torsten
AU  - Haferlach T
LA  - eng
PT  - Journal Article
DEP - 20111205
PL  - United States
TA  - Cytometry B Clin Cytom
JT  - Cytometry. Part B, Clinical cytometry
JID - 101235690
RN  - 0 (CD8 Antigens)
RN  - EC 2.7.10.2 (ZAP-70 Protein-Tyrosine Kinase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - CD8 Antigens/*metabolism
MH  - Chromosome Aberrations
MH  - Female
MH  - Flow Cytometry/methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/genetics/*immunology/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Young Adult
MH  - ZAP-70 Protein-Tyrosine Kinase/metabolism
EDAT- 2011/12/07 06:00
MHDA- 2012/09/01 06:00
CRDT- 2011/12/07 06:00
PHST- 2011/09/30 00:00 [received]
PHST- 2011/11/03 00:00 [revised]
PHST- 2011/11/14 00:00 [accepted]
PHST- 2011/12/07 06:00 [entrez]
PHST- 2011/12/07 06:00 [pubmed]
PHST- 2012/09/01 06:00 [medline]
AID - 10.1002/cyto.b.21002 [doi]
PST - ppublish
SO  - Cytometry B Clin Cytom. 2012 May;82(3):145-50. doi: 10.1002/cyto.b.21002. Epub 
      2011 Dec 5.